NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

RecruitingNA

Sponsor: Inna Chen, MD

Conditions: Pancreatic Cancer, Lung Cancer, Nonsmall Cell

Interventions: Supportive application with integrated weekly PRO

Countries: Denmark

Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with pancreatic and lung cancer have highest rates of unplanned hospitalizations. Investigator initiated prospective "Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)" is to be initiated based on the great need for optimizing treatment care, reducing hospitalizations and improving outcomes.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adult (aged 18 and over)
* Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer
* Written informed consent before any study procedures
* Planning to receive 1st line systemic anticancer therapy within ≤2 weeks
* Performance status: ECOG 0-2
* Access to the internet
* Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member

Exclusion Criteria:

* No mobile device
* Exhibiting signs of overt psychopathology or cognitive dysfunction
* Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments
* Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.

Locations (1)

Herlev, Denmark